CG Oncology (NASDAQ:CGON) Director Acquires $24,814,453.95 in Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Brian Guan-Chyun Liu acquired 371,085 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was purchased at an average price of $66.87 per share, for a total transaction of $24,814,453.95. Following the completion of the purchase, the director directly owned 1,886,236 shares in the company, valued at $126,132,601.32. This trade represents a 24.49% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

CG Oncology Price Performance

NASDAQ:CGON traded up $1.77 on Monday, reaching $73.73. 1,092,859 shares of the company’s stock were exchanged, compared to its average volume of 1,213,217. The firm has a market cap of $6.50 billion, a price-to-earnings ratio of -31.64 and a beta of 0.31. The stock has a fifty day simple moving average of $64.40 and a 200-day simple moving average of $58.11. CG Oncology, Inc. has a 52 week low of $23.65 and a 52 week high of $75.50.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, sell-side analysts predict that CG Oncology, Inc. will post -2.89 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Wolfe Research initiated coverage on CG Oncology in a research report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Royal Bank Of Canada lifted their price target on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Wall Street Zen cut CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. JPMorgan Chase & Co. raised their target price on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, Truist Financial reaffirmed a “buy” rating and set a $82.00 target price (up from $77.00) on shares of CG Oncology in a report on Thursday, May 14th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CG Oncology currently has an average rating of “Moderate Buy” and an average target price of $81.73.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CGON. NFSG Corp bought a new position in shares of CG Oncology in the first quarter worth $34,000. Comerica Bank grew its position in CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after buying an additional 515 shares in the last quarter. LPL Financial LLC increased its stake in CG Oncology by 9.8% in the 4th quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock worth $257,000 after acquiring an additional 551 shares during the last quarter. Whittier Trust Co. of Nevada Inc. bought a new position in CG Oncology in the 4th quarter worth about $27,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of CG Oncology by 33.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after acquiring an additional 972 shares in the last quarter. 26.56% of the stock is owned by institutional investors.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.